Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Frigerio

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters|August 6, 2008
8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK)Marine Desage-El Murr, Celine Cano, Bernard T Golding, et al.
Molecular Cancer Therapeutics|October 8, 2009
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasionSarah E Golding, Elizabeth Rosenberg, Nicholas Valerie, et al.
Bioconjugate Chemistry|May 6, 2014
Bridging disulfides for stable and defined antibody drug conjugatesGeorge Badescu, Penny Bryant, Matthew Bird, et al.
Journal of Medicinal Chemistry|July 17, 2013
1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activityCéline Cano, Kappusamy Saravanan, Chris Bailey, et al.
Frontiers in Pharmacology|July 5, 2022
Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced <i>in vivo</i> PerformanceNick Evans, Ruslan Grygorash, Paul Williams, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 17, 2013
On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium saltsSara Iachettini, Malcolm Fg Stevens, Mark Frigerio, et al.
Journal of Medicinal Chemistry|November 18, 2010
DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotypeCéline Cano, Olivier R Barbeau, Christine Bailey, et al.
Molecular Pharmaceutics|April 21, 2015
In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody RatiosPenny Bryant, Martin Pabst, George Badescu, et al.
Journal of Medicinal Chemistry|March 21, 2007
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinaseJonathan J Hollick, Laurent J M Rigoreau, Celine Cano-Soumillac, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 5, 2017
Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugatesMartin Pabst, William McDowell, Anaïs Manin, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters|August 6, 2008
8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK)Marine Desage-El Murr, Celine Cano, Bernard T Golding, et al.
Molecular Cancer Therapeutics|October 8, 2009
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasionSarah E Golding, Elizabeth Rosenberg, Nicholas Valerie, et al.
Bioconjugate Chemistry|May 6, 2014
Bridging disulfides for stable and defined antibody drug conjugatesGeorge Badescu, Penny Bryant, Matthew Bird, et al.
Journal of Medicinal Chemistry|July 17, 2013
1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activityCéline Cano, Kappusamy Saravanan, Chris Bailey, et al.
Frontiers in Pharmacology|July 5, 2022
Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced <i>in vivo</i> PerformanceNick Evans, Ruslan Grygorash, Paul Williams, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 17, 2013
On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium saltsSara Iachettini, Malcolm Fg Stevens, Mark Frigerio, et al.
Journal of Medicinal Chemistry|November 18, 2010
DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotypeCéline Cano, Olivier R Barbeau, Christine Bailey, et al.
Molecular Pharmaceutics|April 21, 2015
In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody RatiosPenny Bryant, Martin Pabst, George Badescu, et al.
Journal of Medicinal Chemistry|March 21, 2007
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinaseJonathan J Hollick, Laurent J M Rigoreau, Celine Cano-Soumillac, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 5, 2017
Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugatesMartin Pabst, William McDowell, Anaïs Manin, et al.
Pageof 2